Shicai Ye

Prof. Dr. Shicai Ye


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 October 2013 in Genes, Chromosomes and Cancer
Verified
Journal Article
Closed access
PDF file
WWWeiyun Wu
Weiyun Wu
PYPengchun Yang
Pengchun Yang
XFXiao Feng
Xiao Feng
HWHao Wang
Hao Wang
YQYumei Qiu
Yumei Qiu
YZYu Zhou
Yu Zhou

1 January 2014 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
TRTianhua Ren
Tianhua Ren
YQYumei Qiu
Yumei Qiu
WWWeiyun Wu
Weiyun Wu
FXFeng Xiao
Feng Xiao
SYShicai Ye
Shicai Ye
YZYu Zhou
Yu Zhou
To investigate the expression of adenosine A3 receptor (A3AR) in human colonic epithelial cells and the effects of A3AR activation on tumor necrosis factor alpha (TNF-α-) induced inflammation in order to determine its mechanism of action in human colonic epithelial cells, human colonic epithelial cells (HT-29 cells) were treated with different concentrations of 2-Cl-IB-MECA prior to TNF-αstimulation, followed by analysis of NF-κB signaling pathway activation and downstream IL-8 and IL-1βproduction. A3AR mRNA and protein were expressed in HT-29 cells and not altered by changes in TNF-αor 2-Cl-IB-MECA. Pretreatment with 2-Cl-IB-MECA prior to stimulation with TNF-αattenuated NF-κB p65 nuclear translocation as p65 protein decreased in the nucleus of cells and increased in the cytoplasm, inhibited the degradation of IκB-α, and reduced phosphorylated-IκB-αlevel significantly, compared to TNF-α-only-treated groups. Furthermore, 2-Cl-IB-MECA significantly decreased TNF-α-stimulated IL-8 and IL-1βmRNA expression and secretion, compared to the TNF-α-only treated group. These results confirm that A3AR is expressed in human colonic epithelial cells and demonstrate that its activation has an anti-inflammatory effect, through the inhibition of NF-κB signaling pathway, which leads to inhibition of downstream IL-8 and IL-1βexpression. Therefore, A3AR activation may be a potential treatment for gut inflammatory diseases such as inflammatory bowel disease.

22 August 2024 in International Immunopharmacology
Verified
Journal Article
Closed access
CCChangan Chen
Changan Chen
JQJuan-Hua Quan
Juan-Hua Quan
XCXintian Chen
Xintian Chen
TYTingmei Yang
Tingmei Yang
CYCaiyuan Yu
Caiyuan Yu
YWYijie Weng
Yijie Weng

30 January 2025 in Journal of Medical Internet Research
Verified
Journal Article
Open access
YKYanqi Kou
Yanqi Kou
SYShicai Ye
Shicai Ye
YTYuan Tian
Yuan Tian
KYKe Yang
Ke Yang
LQLing Qin
Ling Qin
YYYuping Yang
Yuping Yang
Background: Gastrointestinal bleeding (GIB) is a severe and potentially life-threatening complication in patients with acute myocardial infarction (AMI), significantly affecting prognosis during hospitalization. Early identification of high-risk patients is essential to reduce complications, improve outcomes, and guide clinical decision-making. Objective: This study aimed to develop and validate a machine learning (ML)–based model for predicting in-hospital GIB in patients with AMI, identify key risk factors, and evaluate the clinical applicability of the model for risk stratification and decision support. Methods: A multicenter retrospective cohort study was conducted, including 1910 patients with AMI from the Affiliated Hospital of Guangdong Medical University (2005-2024). Patients were divided into training (n=1575) and testing (n=335) cohorts based on admission dates. For external validation, 1746 patients with AMI were included in the publicly available MIMIC-IV (Medical Information Mart for Intensive Care IV) database. Propensity score matching was adjusted for demographics, and the Boruta algorithm identified key predictors. A total of 7 ML algorithms—logistic regression, k-nearest neighbors, support vector machine, decision tree, random forest (RF), extreme gradient boosting, and neural networks—were trained using 10-fold cross-validation. The models were evaluated for the area under the receiver operating characteristic curve, accuracy, sensitivity, specificity, recall, F1-score, and decision curve analysis. Shapley additive explanations analysis ranked variable importance. Kaplan-Meier survival analysis evaluated the impact of GIB on short-term survival. Multivariate logistic regression assessed the relationship between coronary heart disease (CHD) and in-hospital GIB after adjusting for clinical variables. Results: The RF model outperformed other ML models, achieving an area under the receiver operating characteristic curve of 0.77 in the training cohort, 0.77 in the testing cohort, and 0.75 in the validation cohort. Key predictors included red blood cell count, hemoglobin, maximal myoglobin, hematocrit, CHD, and other variables, all of which were strongly associated with GIB risk. Decision curve analysis demonstrated the clinical use of the RF model for early risk stratification. Kaplan-Meier survival analysis showed no significant differences in 7- and 15-day survival rates between patients with AMI with and without GIB (P=.83 for 7-day survival and P=.87 for 15-day survival). Multivariate logistic regression showed that CHD was an independent risk factor for in-hospital GIB (odds ratio 2.79, 95% CI 2.09-3.74). Stratified analyses by sex, age, occupation, marital status, and other subgroups consistently showed that the association between CHD and GIB remained robust across all subgroups. Conclusions: The ML-based RF model provides a robust and clinically applicable tool for predicting in-hospital GIB in patients with AMI. By leveraging routinely available clinical and laboratory data, the model supports early risk stratification and personalized preventive strategies.

20 October 2025 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
BCBoxian Chen
Boxian Chen
YYYuping Yang
Yuping Yang
MLMouji Liang
Mouji Liang
YKYanqi Kou
Yanqi Kou
RYRuyin Ye
Ruyin Ye
SYShicai Ye
Shicai Ye
Background: Magnesium deficiency is common in patients with cirrhosis, but there is a lack of real-world evidence to support the effect of magnesium supplementation on prognosis.Objective: To explore whether magnesium sulfate supplementation is beneficial for patients with cirrhosis using data from the MIMIC-IV database.Methods: Patients with cirrhosis were divided into magnesium sulfate group and non-magnesium sulfate group according to medication use during hospitalization after admission to the intensive care unit (ICU). In-hospital all-cause mortality was the primary outcome, and 180-day all-cause mortality was the secondary outcome. Propensity score matching (PSM) method, univariate and multivariate regression analysis were used to evaluate the effect of magnesium sulfate on prognosis, and Kaplan-Meier curves, subgroup analysis and sensitivity analysis were performed to clarify the stability of the results.Results: The prematched cohort included 3,312 patients, while the propensity score matched cohort included 1,308 patients. In the PSM analysis, the in-hospital all-cause mortality in the magnesium sulfate group was 22.0% (144/654), and that in the non-use group was 31.0% (203/654). Magnesium sulfate use was associated with lower in-hospital mortality (odds ratio [OR], 0.47; 95% confidence interval [CI], 0.33–0.69; P < 0.001) and reduced all-cause mortality at 180 days after ICU admission (hazard ratio [HR], 0.61; 95% CI, 0.51–0.72; P < 0.001). Sensitivity analyses confirmed the robustness of these results.Conclusion: Magnesium sulfate use is associated with reduced in-hospital and 180-day all-cause mortality in ICU patients with cirrhosis, which needs to be verified in prospective studies.

Verified
Journal Article
Open access
PDF file
LCLijiao Cui
Lijiao Cui
SYShicai Ye
Shicai Ye
ZGZhiwei Gu
Zhiwei Gu
GZGuixia Zhang
Guixia Zhang
TCTingen Chen
Tingen Chen
CYCaiyuan Yu
Caiyuan Yu
Inflammatory bowel disease (IBD) and rheumatoid arthritis (RA) are chronic inflammatory diseases that share immune dysregulation and mitochondrial dysfunction. Understanding the molecular mechanisms linking these diseases to mitochondrial dysfunction is crucial for developing novel diagnostic and therapeutic strategies. Datasets related to IBD and RA were obtained from the Gene Expression Omnibus database. Differentially expressed mitochondrial dysfunction-related genes (MDRGs) were identified using differential expression analysis. Weighted gene co-expression network analysis was performed to identify crosstalk genes (CGs). Logistic regression and support vector machine (SVM) models were constructed using least absolute shrinkage and selection operator regression to identify hub genes. Additionally, the differential expression and diagnostic value of the hub genes were verified using quantitative reverse transcriptase–polymerase chain reaction and validation sets. Finally, immune infiltration analysis was conducted to assess the role of immune cells in IBD and RA. A total of 87 CGs associated with mitochondrial dysfunction were identified between IBD and RA, among which PDIA4 and DUSP6 were identified as hub genes. Twenty proteins, including ERO1A, MAPK7, and P4HB, were identified as key proteins that interacted with PDIA4 and DUSP6. The area under the curve (AUC) of the ROC curves for IBD and RA based on the DUSP6 and PDIA4 diagnostic models were 0.664 and 0.856, respectively. The qRT-PCR results indicated that PDIA4 and DUSP6 were overexpressed in IBD and RA. Seven immune cell types, including activated B cells, activated dendritic cells, and eosinophils showed significant differences in the IBD and RA groups. Our findings highlight the close association between IBD, RA, and mitochondrial dysfunction. PDIA4 and DUSP6 may serve as potential biomarkers of mitochondrial dysfunction in patients with IBD and RA.